Document is current
Any future updates will be listed below
-
Authors
Cappell, Mitchell S. https://orcid.org/0000-0003-3445-5428
- License Information
-
More Information
Article History
First Online: 25 August 2020
Compliance with Ethical Standards
:
: None. Dr. Cappell did not receive any financial support for writing this editorial. In particular, Dr. Cappell, as a consultant of the United States Food and Drug Administration (FDA) Advisory Committee for Gastrointestinal Drugs, affirms that this paper does not discuss any proprietary, confidential, pharmaceutical data submitted to the FDA. Dr. Cappell was also a member of the speaker’s bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik until more than 2 years ago. Dr. Cappell received a one-time honorarium from Shire and Mallinckrodt more than 2 years ago. This work does not discuss any drug manufactured or marketed by AstraZeneca, Daiichi Sankyo, Shire, or Mallinckrodt.
Free to read: This content has been made available to all.
